• search
Early Phase Formulation Development Early Phase Formulation Development

Early Phase Formulation Development

Our early-phase formulation development services are tailored to address specific drug delivery challenges.

Our early-phase formulation development services help to resolve drug delivery challenges encountered at both preclinical and clinical development stages of small molecules and peptides. We offer specific solutions to your preformulation and formulation needs through customized development strategies and designs.

Our expert team of scientists have successfully delivered projects in wide range of areas like incomplete dissolution, low solubility, low oral bioavailability and targeted drug delivery through in-depth molecular characterization, various solubilization and enabling technologies.

Speak to our experts

Our Services for Preclinical Formulation Development Include

Many hits and lead NCEs get shelved from pharmacological and toxicity screening despite high potency because of poor bioavailability or suboptimal formulation. As a leading CDMO company, we have more than a decade of experience in helping our clients overcome these challenges by enabling preclinical and GLP toxicology studies.

Our preclinical formulation development approach considers but is not limited to

Oral formulation

  • Suspension
  • Solution
  • Solid dispersion
  • Enteric solid dispersion
  • Lipid based delivery (Emulsion/SMEDDS)
  • Micro/Nano-suspension

Parenteral formulation

  • Solution
  • Lyophilization
  • Emulsion
  • Nano-suspension

Oral Bioavailability Enhancement Services Include

Our formulation team has the expertise in troubleshooting complex problems by banking various oral bioavailability enhancement strategies to accelerate your drug discovery program to the next phase.

Formulation development strategies are:

Solubilization strategies

  • Micellar solubilization
  • Complexation
  • pH modification/buffering
  • Cosolvents
  • Anti-precipitating agents

Enabling technologies

  • Solid dispersions
    • Spray drying
    • Rota-evaporation
    • Spray granulation technology
    • Hot melt extrusion
  • Particle size reduction
    • Micronization (Air-jet mill)
    • Nanosizing
  • Lipid-based drug delivery systems
    • Emulsion
    • SEDDS/SMEDDS
    • Lipid formulation filled in Soft gelatin capsules
Early Phase Formulation Development

Our data-driven approach enables our partners to advance candidates and select the most optimal formulation for a specific drug development phase.

Why Aurigene Early Phase Formulation Development Services?

Services from early formulation to clinical manufacturing

Experience with advanced formulation technologies

Integration with biology services for in vitro and in vivo studies

Global accreditations

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

CAPTCHA
この質問はあなたが人間の訪問者であるかどうかをテストし、自動化されたスパム送信を防ぐためのものです。

rightCaptcha

寡核苷酸作为一种新型治疗方式

JULY 02, 2021

寡核苷酸作为一种新型治疗方式

寡核苷酸作为一种治疗类别是发现用于治疗人类疾病的新的重要治疗剂的革命性方法。基于 RNA 的干预有时适用于其他方式不起作用的情况。例如,它可能有助于治疗先天性新陈代谢错误、遗传疾病和罕见病 寡核苷酸疗法是将化学修饰的寡核苷酸用于治疗目的。寡核苷�...

Read More

Methoxy Polyethylene Glycol (m-PEGs)

Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...

Read More

Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones

2020

A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack